EUVIMEDEUVIMED entdecken
Crossref

Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy

Shu-Yi Huang iD, Shu-Fen Chen, Mei Cui, Meng Zhao, Xue-Ning Shen, Yu Guo, Ya-Ru Zhang, Wei Zhang, Hui-Fu Wang, Yu-Yuan Huang, Wei Cheng iD, Chuan-Tao Zuo iD und 2 weitere

Movement Disorders · 2023

DOI: 10.1002/mds.29339 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders, 2023. Verfasst von Shu-Yi Huang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Fronti…. Hauptthemen laut MEDLINE: Multiple System Atrophy, Parkinson Disease, Parkinsonian Disorders, Supranuclear Palsy, Progressive. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Development of disease‐modifying therapeutic trials of progressive supranuclear palsy (PSP) urges the need for sensitive fluid biomarkers.

Objectives

The objectives of this study were to explore the utility of plasma biomarkers in the diagnosis, differential diagnosis, and assessment of disease severity, brain atrophy, and tau deposition in PSP.

Methods

Plasma biomarkers were measured using a single‐molecule array in a cohort composed of patients with PSP, Parkinson's disease (PD), multiple system atrophy with predominant parkinsonism (MSA‐P), and healthy controls (HCs).

Results

Plasma neurofilament light chain (NfL) outperformed other plasma makers (ie, glial fibrillary acidic protein [GFAP], phosphorylated‐tau 181 [p‐tau181], amyloid‐β 1–40, amyloid‐β 1–42) in identifying PSP from HC (area under the curve [AUC] = 0.904) and from MSA‐P (AUC = 0.711). Plasma GFAP aided in distinguishing PSP from HC (AUC = 0.774) and from MSA‐P (AUC = 0.832). It correlated with brainstem atrophy and higher regional tau accumulation. However, plasma p‐tau181 neither helped in diagnosis nor was it associated with clinical or neuroimaging measures.

Conclusions

Plasma NfL and GFAP showed different values in differentiating PSP from HC or controls with other forms of neurodegenerative parkinsonism and detecting disease severity, brain atrophy, or tau deposition in PSP. © 2023 International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple System AtrophyParkinson DiseaseParkinsonian DisordersSupranuclear Palsy, ProgressiveHumansBiomarkersPositron-Emission Tomographytau Proteins

Substanzen

Biomarkerstau ProteinsMAPT protein, human

Autor:innen und Institutionen

  • Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan Universi…
  • Department of Neurology, The First Hospital of Jilin University, Changchun, China.
  • Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, China.
  • PET Center, Huashan Hospital, Fudan University, Shanghai, China.

ORCID-Profile: Shu-Yi Huang, Wei Cheng, Chuan-Tao Zuo, Jin-Tai Yu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Huang, S. Y., Chen, S. F., Cui, M., Zhao, M., Shen, X. N., Guo, Y., Zhang, Y. R., Zhang, W., Wang, H. F., Huang, Y. Y., Cheng, W., Zuo, C. T., Dong, Q., & Yu, J. T. (2023). Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy. Movement Disorders. https://doi.org/10.1002/mds.29339

Vancouver

Huang SY, Chen SF, Cui M, Zhao M, Shen XN, Guo Y, et al. Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy. Movement Disorders. 2023. doi:10.1002/mds.29339

BibTeX
@article{Huang2023,
  author = {Huang, Shu-Yi and Chen, Shu-Fen and Cui, Mei and Zhao, Meng and Shen, Xue-Ning and Guo, Yu and Zhang, Ya-Ru and Zhang, Wei and Wang, Hui-Fu and Huang, Yu-Yuan and Cheng, Wei and Zuo, Chuan-Tao and Dong, Qiang and Yu, Jin-Tai},
  title = {Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy},
  journal = {Movement Disorders},
  year = {2023},
  doi = {10.1002/mds.29339}
}
Kostenlos starten →